Kejal Kantarci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6224308/publications.pdf

Version: 2024-02-01

258 papers	20,448 citations	15466 65 h-index	13338 130 g-index
260 all docs	260 docs citations	260 times ranked	19080 citing authors

#	Article	IF	Citations
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
2	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.4	581
3	Clinical Proton MR Spectroscopy in Central Nervous System Disorders. Radiology, 2014, 270, 658-679.	3.6	524
4	An operational approach to National Institute on Agingâ€“Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology, 2012, 71, 765-775.	2.8	520
5	Understanding the impact of sex and gender in Alzheimer's disease: A call to action. Alzheimer's and Dementia, 2018, 14, 1171-1183.	0.4	468
6	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. NeuroImage, 2008, 39, 1186-1197.	2.1	391
7	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
8	Non-Stationarity in the â€œResting Brainâ€™sâ€•Modular Architecture. PLoS ONE, 2012, 7, e39731.	1.1	382
9	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.5	365
10	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain, 2012, 135, 765-783.	3.7	322
11	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	3.7	309
12	Mild Cognitive Impairment and Alzheimer Disease: Regional Diffusivity of Water. Radiology, 2001, 219, 101-107.	3.6	293
13	Spread of pathological tau proteins through communicating neurons in human Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2612.	5.8	283
14	Methodological consensus on clinical proton MRS of the brain: Review and recommendations. Magnetic Resonance in Medicine, 2019, 82, 527-550.	1.9	280
15	Clinicopathologic and¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimerâ€™s disease spectrum. Brain, 2015, 138, 1370-1381.	3.7	270
16	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	1.4	249
17	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	3.7	222
18	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218

#	Article	IF	Citations
19	The Role of Biomarkers in Clinical Trials for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 6-15.	0.6	203
20	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. Brain, 2010, 133, 540-556.	3.7	195
21	Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clinics of North America, 2003, 13, 197-209.	0.5	193
22	Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology, 2013, 81, 2032-2038.	1.5	191
23	Patterns of Atrophy Differ Among Specific Subtypes of Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 1130.	4.9	185
24	Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2007, 28, 1330-1339.	1.5	185
25	Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology, 2014, 82, 1132-1141.	1.5	180
26	Imaging correlates of posterior cortical atrophy. Neurobiology of Aging, 2007, 28, 1051-1061.	1.5	176
27	Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 2091-2105.	1.5	162
28	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162
29	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
30	Brain injury biomarkers are not dependent on Î²â€amyloid in normal elderly. Annals of Neurology, 2013, 73, 472-480.	2.8	155
31	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	2.1	155
32	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	2.1	152
33	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
34	Effect of lifestyle activities on alzheimer disease biomarkers and cognition. Annals of Neurology, 2012, 72, 730-738.	2.8	149
35	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem¹H MR Spectroscopy Metabolite Measurements¹. Radiology, 2008, 248, 210-220.	3.6	147
36	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	4.5	146

#	Article	IF	Citations
37	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
38	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimer's and Dementia, 2015, 11, 740-756.	0.4	142
39	Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2002, 14, 198-207.	0.7	135
40	Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation. Journal of Nuclear Medicine, 2014, 55, 759-764.	2.8	134
41	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129
42	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	3.7	126
43	Vascular Imaging Abnormalities and Cognition. Stroke, 2015, 46, 433-440.	1.0	125
44	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
45	Identification of Anonymous MRI Research Participants with Face-Recognition Software. New England Journal of Medicine, 2019, 381, 1684-1686.	13.9	124
46	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	1.7	117
47	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
48	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
49	Clinical Correlates of White Matter Tract Degeneration in Progressive Supranuclear Palsy. Archives of Neurology, 2011, 68, 753-60.	4.9	110
50	1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. Journal of the International Neuropsychological Society, 2002, 8, 934-942.	1.2	109
51	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	1.5	108
52	Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain, 2006, 129, 3103-3114.	3.7	105
53	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. Archives of Neurology, 2012, 69, 856-67.	4.9	99
54	The Kronos Early Estrogen Prevention Study (KEEPS). Menopause, 2019, 26, 1071-1084.	0.8	97

#	Article	IF	Citations
55	MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology, 2013, 81, 126-133.	1.5	95
56	Early Postmenopausal Transdermal 17Î²-Estradiol Therapy and Amyloid-Î² Deposition. Journal of Alzheimer's Disease, 2016, 53, 547-556.	1.2	94
57	Preeclampsia and cognitive impairment later in life. American Journal of Obstetrics and Gynecology, 2017, 217, 74.e1-74.e11.	0.7	93
58	Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. American Journal of Neuroradiology, 2003, 24, 843-9.	1.2	92
59	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.5	91
60	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. NeuroImage, 2011, 55, 522-531.	2.1	90
61	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology, 2013, 80, 911-918.	1.5	86
62	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	4.5	81
63	Quantitative magnetic resonance techniques as surrogate markers of Alzheimerâ€™s disease. NeuroRx, 2004, 1, 196-205.	6.0	80
64	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. Archives of Neurology, 2008, 65, 1621-8.	4.9	75
65	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
66	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.5	73
67	Ante mortem amyloid imaging and Î²-amyloid pathology in a case with dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 878-885.	1.5	69
68	The limbic and neocortical contribution of Î±â€synuclein, tau, and amyloid Î² to disease duration in dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 330-339.	0.4	69
69	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	4.5	69
70	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
71	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	3.7	68
72	Untreated Type 2 Diabetes and Its Complications Are Associated With Subcortical Infarctions. Diabetes Care, 2011, 34, 184-186.	4.3	66

#	Article	IF	Citations
73	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With Î²-Amyloidosis. JAMA Neurology, 2013, 70, 1030.	4.5	65
74	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
75	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain, 2012, 135, 2470-2477.	3.7	64
76	Magnetic resonance spectroscopy, Î²-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology, 2011, 77, 951-958.	1.5	63
77	Fractional Anisotropy of the Fornix and Hippocampal Atrophy in AlzheimerÃ¢â‚¬â„¢s Disease. Frontiers in Aging Neuroscience, 2014, 6, 316.	1.7	63
78	Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S70-6.	0.9	63
79	Neuroimaging Correlates of Cerebral Microbleeds. Stroke, 2017, 48, 2964-2972.	1.0	63
80	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
81	Proton MRS in mild cognitive impairment. Journal of Magnetic Resonance Imaging, 2013, 37, 770-777.	1.9	62
82	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
83	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
84	Magnetic resonance spectroscopy in Alzheimer’s disease. Neuropsychiatric Disease and Treatment, 2013, 9, 687.	1.0	61
85	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
86	Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldtâ€“Jakob disease. Clinical Neurophysiology, 2003, 114, 1724-1728.	0.7	59
87	Focal hemosiderin deposits and Î²â€amyloid load in the ADNI cohort. Alzheimer's and Dementia, 2013, 9, S116-23.	0.4	59
88	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology, 2013, 81, 1681-1689.	1.5	58
89	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.4	58
90	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	4.5	57

#	Article	IF	Citations
91	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology, 2018, 90, e1404-e1412.	1.5	57
92	Cervical spinal cord atrophy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e435.	3.1	57
93	The Role of Diffusion Tensor Imaging in Detecting Microstructural Changes in Prodromal <scp>A</scp>lzheimer's Disease. CNS Neuroscience and Therapeutics, 2014, 20, 3-9.	1.9	55
94	Arguing against the proposed definition changes of PD. Movement Disorders, 2016, 31, 1619-1622.	2.2	55
95	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.5	55
96	Midlife and Lateâ€Life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. Journal of the American Heart Association, 2017, 6, .	1.6	54
97	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.5	53
98	Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause. Biology of Sex Differences, 2013, 4, 6.	1.8	52
99	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
100	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
101	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
102	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism and Related Disorders, 2014, 20, 493-498.	1.1	49
103	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	2.8	49
104	Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment. American Journal of Neuroradiology, 2010, 31, 1247-1253.	1.2	48
105	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
106	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
107	Effects of hormone therapy on brain structure. Neurology, 2016, 87, 887-896.	1.5	47
108	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47

#	Article	IF	Citations
109	Myelopathy in BehÃ§et's disease: The Bagel Sign. Annals of Neurology, 2017, 82, 288-298.	2.8	46
110	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45
111	Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Medicine, 2015, 16, 1502-1510.	0.8	45
112	Magnetic Resonance Spectroscopy in Common Dementias. Neuroimaging Clinics of North America, 2013, 23, 393-406.	0.5	44
113	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.5	44
114	Plasma sphingolipid changes with autopsyâ€confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	1.2	44
115	Multipleâ€dose ponezumab for mildâ€toâ€moderate Alzheimer's disease: Safety and efficacy. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 339-347.	1.8	43
116	Acrossâ€vendor standardization of semiâ€LASER for singleâ€voxel MRS at 3T. NMR in Biomedicine, 2021, 34, e4218.	1.6	43
117	APOE and cortical superficial siderosis in CAA. Neurology, 2019, 93, e358-e371.	1.5	42
118	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
119	Lesional REM sleep behavior disorder localizes to the dorsomedial pons. Neurology, 2014, 83, 1871-1873.	1.5	40
120	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	1.0	40
121	Association of common genetic variants with brain microbleeds. Neurology, 2020, 95, e3331-e3343.	1.5	40
122	Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting. Magnetic Resonance in Medicine, 2018, 79, 1241-1250.	1.9	38
123	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
124	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. NeuroImage, 2021, 231, 117845.	2.1	38
125	A deep learning framework identifies dimensional representations of Alzheimerâ€™s Disease from brain structure. Nature Communications, 2021, 12, 7065.	5.8	38
126	White Matter Reference Region in PET Studies of ¹¹C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-Î² Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	2.8	37

#	Article	IF	Citations
127	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
128	Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. Brain Communications, 2020, 2, fcaa025.	1.5	37
129	APOE3 Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
130	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	1.5	35
131	Loss of Ovarian Hormones and Accelerated Somatic and Mental Aging. Physiology, 2018, 33, 374-383.	1.6	35
132	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	1.4	34
133	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
134	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
135	AutoVOI: realâ€time automatic prescription of volumeâ€ofâ€interest for single voxel spectroscopy. Magnetic Resonance in Medicine, 2018, 80, 1787-1798.	1.9	32
136	Association of white matter microstructural integrity with cognition and dementia. Neurobiology of Aging, 2019, 83, 63-72.	1.5	32
137	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
138	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer's and Dementia, 2020, 16, 22-36.	0.4	32
139	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31
140	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.5	31
141	Magnetic resonance markers for early diagnosis and progression of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2005, 5, 663-670.	1.4	30
142	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. Journal of Alzheimer's Disease, 2016, 55, 1069-1082.	1.2	30
143	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
144	Cohort profile: the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA). BMJ Open, 2017, 7, e018861.	0.8	30

#	Article	IF	Citations
145	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	1.4	30
146	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
147	Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiBâ€PET Study. Journal of Neuroimaging, 2017, 27, 630-636.	1.0	29
148	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurology, 2022, 79, 592.	4.5	29
149	Elevated occipital Î²-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1357-1364.	0.9	28
150	Reproductive history and progressive multiple sclerosis risk in women. Brain Communications, 2020, 2, fcaa185.	1.5	28
151	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	1.2	27
152	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27
153	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	1.5	27
154	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
155	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	4.5	27
156	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
157	Long-Term Exercise Training for an Individual With Mixed Corticobasal Degeneration and Progressive Supranuclear Palsy Features: 10-Year Case Report Follow-up. Physical Therapy, 2014, 94, 289-296.	1.1	26
158	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimer's and Dementia, 2014, 10, 779-789.	0.4	26
159	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
160	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
161	Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. NeuroImage, 2011, 54, 985-991.	2.1	25
162	Clinical Characterization of a Kindred With a Novel 12-Octapeptide Repeat Insertion in the Prion Protein Gene. Archives of Neurology, 2011, 68, 1165.	4.9	25

#	Article	IF	Citations
163	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. Neurology, 2020, 94, e15-e29.	1.5	25
164	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Neuroimaging, 2015, 25, 269-274.	1.0	24
165	Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women. Journal of Neurology, 2017, 264, 938-945.	1.8	24
166	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
167	Role of biomarkers in studies of presymptomatic Alzheimer's disease. , 2005, 1, 145-151.		23
168	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	4.5	23
169	Staging tau pathology with tau PET in Alzheimerâ€™s disease: a longitudinal study. Translational Psychiatry, 2021, 11, 483.	2.4	23
170	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
171	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.5	22
172	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
173	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
174	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	1.5	21
175	Brain volumetric deficits in MAPT mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	1.7	21
176	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	1.5	20
177	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117.	1.2	19
178	Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. Journal of Hypertension, 2017, 35, 2479-2485.	0.3	19
179	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
180	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.5	19

#	Article	IF	Citations
181	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	2.8	19
182	Tauâ€Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 751-762.	2.8	19
183	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19
184	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.5	18
185	Investigation of white matter PiB uptake as a marker of white matter integrity. Annals of Clinical and Translational Neurology, 2019, 6, 678-688.	1.7	18
186	Confirmation of ¹²³I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. Journal of Nuclear Medicine, 2020, 61, 1628-1635.	2.8	18
187	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
188	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
189	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 5-14.	1.2	17
190	Regional T₁ relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure. Magnetic Resonance in Medicine, 2017, 77, 774-778.	1.9	17
191	Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis. Menopause, 2018, 25, 625-634.	0.8	17
192	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
193	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	2.8	17
194	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
195	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
196	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.5	16
197	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
198	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 317, R912-R920.	0.9	15

#	Article	IF	Citations
199	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
200	Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2014, 10, 62-66.	0.4	14
201	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
202	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
203	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
204	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
205	Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration. Frontiers in Neurology, 2020, 11, 80.	1.1	13
206	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
207	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
208	Risk factors of neurovascular ageing in women. Journal of Neuroendocrinology, 2020, 32, e12777.	1.2	12
209	Clinicopathological and ¹²³Iâ€<scp>FP</scp>â€<scp>CIT SPECT</scp> correlations in patients with dementia. Annals of Clinical and Translational Neurology, 2018, 5, 376-381.	1.7	11
210	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11
211	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1495.	5.8	11
212	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
213	Personal, reproductive, and familial characteristics associated with bilateral oophorectomy in premenopausal women: A population-based case-control study. Maturitas, 2018, 117, 64-77.	1.0	10
214	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
215	Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: A case series. Neurocase, 2012, 18, 1-12.	0.2	9
216	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. Journal of Neuroimaging, 2019, 29, 624-629.	1.0	9

#	Article	IF	Citations
217	Menopausal hormone therapy, blood thrombogenicity, and development of white matter hyperintensities in women of the Kronos Early Estrogen Prevention Study. Menopause, 2020, 27, 305-310.	0.8	9
218	Magnetic resonance spectroscopy in the rodent brain: Experts' consensus recommendations. NMR in Biomedicine, 2021, 34, e4325.	1.6	9
219	Decreased glutamine and glutamate: an early biomarker of neurodegeneration. International Psychogeriatrics, 2021, 33, 1-2.	0.6	9
220	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	1.0	9
221	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	1.5	9
222	Associations of pituitary-ovarian hormones and white matter hyperintensities in recently menopausal women using hormone therapy. Menopause, 2020, 27, 872-878.	0.8	8
223	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
224	A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12299.	1.2	8
225	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
226	Development of ¹ H MRS biomarkers for tracking early predementia Alzheimer disease. Neurology, 2019, 92, 209-210.	1.5	7
227	Long-term ovarian hormone deprivation alters functional connectivity, brain neurochemical profile and white matter integrity in the Tg2576 amyloid mouse model of Alzheimer's disease. Neurobiology of Aging, 2021, 102, 139-150.	1.5	7
228	Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. Neurology, 2014, 83, 1771-1772.	1.5	6
229	Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder. Brain, 2016, 139, 1005-1007.	3.7	6
230	Face recognition from research brain PET: An unexpected PET problem. NeuroImage, 2022, 258, 119357.	2.1	6
231	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	1.4	5
232	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. Frontiers in Neurology, 2021, 12, 615024.	1.1	5
233	Sleep quality and cortical amyloid-Î² deposition in postmenopausal women of the Kronos early estrogen prevention study. NeuroReport, 2021, 32, 326-331.	0.6	5
234	Plugâ€andâ€play advanced magnetic resonance spectroscopy. Magnetic Resonance in Medicine, 2022, 87, 2613-2620.	1.9	5

#	Article	IF	Citations
235	Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy. Annals of Neurology, 2022, 92, 358-363.	2.8	5
236	Diffusion Tensor Imaging in Alzheimers Disease. Current Medical Imaging, 2011, 7, 28-33.	0.4	4
237	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
238	Peripheral Markers of Neurovascular Unit Integrity and Amyloid-Î² in the Brains of Menopausal Women. Journal of Alzheimer's Disease, 2021, 80, 397-405.	1.2	4
239	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
240	An MRIâ€Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. Journal of Neuroimaging, 2016, 26, 264-268.	1.0	3
241	Neuroimaging in Alzheimer Disease. , 2006, , 142-159.		3
242	MR spectroscopy, APOE genotype, and evolving Î²-amyloid pathology. Neurology, 2016, 86, 1750-1751.	1.5	2
243	[O2â€“07â€“06]: CHANGES IN BRAIN STRUCTURE THREE YEARS AFTER THE END OF MENOPAUSAL HORMONE THERAPIES IN A RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2017, 13, P570.	0.4	2
244	Reply to letter: Basis of cingulate island sign may differ in dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 761-762.	2.2	2
245	MRS in Early and Presymptomatic Carriers of a Novel Octapeptide Repeat Insertion in the Prion Protein Gene. Journal of Neuroimaging, 2013, 23, 409-413.	1.0	1
246	Multimodal imaging in RBD â€” present and future. Nature Reviews Neurology, 2018, 14, 574-576.	4.9	1
247	Proton MR spectroscopy in aging and dementia. , 0, , 618-629.		0
248	Imaging markers offer promise. Neurology, 2012, 79, 2296-2297.	1.5	0
249	Early indications of magnetic resonance spectroscopy changes associated with Î²-amyloid load in the cognitively normal. Future Neurology, 2012, 7, 117-118.	0.9	0
250	Dementia and Alzheimer Disease: Evidence-Based Neuroimaging. , 2013, , 283-298.		0
251	Past hormone therapy in older women. Neurology, 2014, 82, 380-381.	1.5	0
252	Magnetic Resonance Spectroscopy in Dementia. , 2016, , 55-70.		0

#	Article	IF	Citations
253	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.4	0
254	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. Journal of Human Hypertension, 2018, 32, 385-385.	1.0	0
255	Reply to â€œAmyloid Positron Emission Tomography in Multiple Sclerosis: Between Amyloid Deposition and Myelin Damageâ€. Annals of Neurology, 2020, 87, 988-989.	2.8	0
256	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. Journal of Magnetic Resonance Imaging, 2022, 55, 1907-1909.	1.9	0
257	10 Neuroimaging in Alzheimer Disease. , 2011, , 167-182.		0
258	Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures. Acta Neuropathologica Communications, 2022, 10, .	2.4	0